Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. LFWD
LFWD logo

LFWD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
6.350
Open
6.030
VWAP
6.21
Vol
6.50K
Mkt Cap
9.68M
Low
5.935
Amount
40.40K
EV/EBITDA(TTM)
--
Total Shares
1.52M
EV
7.30M
EV/OCF(TTM)
--
P/S(TTM)
0.24
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
Show More

Events Timeline

(ET)
2026-03-02
08:30:00
Lifeward Partners with Shirley Ryan AbilityLab for ReWalk Exoskeleton Clinics
select
2026-02-25 (ET)
2026-02-25
08:20:00
Lifeward Acquires Skelable Technology Assets for $480,000
select
2026-02-23 (ET)
2026-02-23
20:00:00
Rewalk Robotics LTD Trading Halted, News Pending
select
2026-02-17 (ET)
2026-02-17
08:20:00
Lifeward Secures Aetna Approval for ReWalk Exoskeleton
select
2026-01-13 (ET)
2026-01-13
08:10:00
Lifeward Enters Strategic Partnership with Oramed
select
2026-01-13
08:10:00
Oramed and Lifeward Sign Binding Strategic Transaction Agreement
select
2025-12-19 (ET)
2025-12-19
16:20:00
Lifeward Appoints Bob Marshall as Chairman of the Board
select
2025-12-17 (ET)
2025-12-17
08:10:00
Lifeward Signs International Distribution Agreement with Verita Neuro
select
2025-12-03 (ET)
2025-12-03
08:20:00
Lifeward Receives Humana Medicare Approval for ReWalk 7
select

News

stocktwits
8.5
02-20stocktwits
Lifeward Announces 1-for-12 Reverse Stock Split
  • Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
  • Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
  • Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
  • Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
NASDAQ.COM
7.5
01-13NASDAQ.COM
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
  • Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
  • Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
  • Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
  • Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Globenewswire
5.0
2025-12-19Globenewswire
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
  • Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
  • Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
  • Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
  • Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.
Newsfilter
5.0
2025-12-19Newsfilter
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
  • Leadership Transition: Lifeward has announced the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating a strategic shift in the company's executive leadership.
  • Experienced Successor: Bob Marshall has been a board member since 2024 and served as Chair of the Audit Committee, and his financial leadership and expertise in the healthcare public company sector are expected to significantly support Lifeward's strategic growth plans, enhancing its competitive edge in the medical technology field.
  • Contribution of Predecessor: Joseph Turk's leadership has driven the company's development, and the board expressed gratitude for his contributions during his tenure, reflecting the company's commitment to leadership stability, which is crucial for maintaining investor confidence.
  • Future Outlook: The appointment of the new chairman aligns with Lifeward's long-term strategic goals, aiming to improve patient care and outcomes through ongoing innovation and market expansion, thereby further solidifying its leadership position in the medical technology sector.
Newsfilter
7.5
2025-12-17Newsfilter
Lifeward Partners with Verita Neuro to Expand ReWalk Market Access
  • Market Expansion: Lifeward's international distribution agreement with Singapore's Verita Neuro aims to promote the ReWalk Personal Exoskeleton in Mexico, Thailand, and the UAE, potentially reaching over 25,000 spinal cord injury patients and significantly enhancing global market penetration.
  • Innovative Delivery Model: The new agreement integrates ReWalk into Verita's multi-modal treatment protocols, with personalized setup and training in inpatient rehabilitation programs expected to accelerate clinical adoption and improve patient recovery outcomes.
  • Market Potential: With over 7 million spinal cord injury survivors globally, Lifeward's total addressable market for ReWalk is estimated at $1.75 billion, indicating substantial growth potential in the medical technology sector.
  • Strategic Alignment: This partnership complements Lifeward's existing distribution and reimbursement networks in the U.S. and Germany, aiming to drive long-term sustainable growth through a capital-efficient collaborative model that enhances the company's competitive edge in international markets.
Newsfilter
7.5
2025-12-03Newsfilter
Lifeward Secures Humana Approval for ReWalk 7 Exoskeleton
  • Market Leadership: Lifeward's approval from Humana Medicare Advantage Plan enables nearly half of all Medicare Advantage enrollees to access the ReWalk 7 exoskeleton, further solidifying its leadership position in the medical technology sector.
  • Revenue Growth Potential: This approval is expected to enhance Lifeward's revenue and cash flow dynamics, thereby establishing a stronger foundation for sustainable growth in the U.S. market.
  • Promotion of Innovative Technology: Humana's endorsement reflects its commitment to supporting innovative medical technologies aimed at providing more reliable exoskeleton solutions for spinal cord injury patients, thereby improving their quality of life.
  • Accelerated Payer Adoption: As coverage for the ReWalk exoskeleton expands, Lifeward is experiencing a faster pace of prior authorization approvals, which not only increases reimbursement predictability but also creates favorable conditions for the company's future market expansion.
Wall Street analysts forecast LFWD stock price to rise
1 Analyst Rating
Wall Street analysts forecast LFWD stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$13
AI Analysis
2025-11-18
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$13
AI Analysis
2025-11-18
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Lifeward to $4.50 from $13 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's operational changes, regulatory wins and changes in payor dynamics underway bode well for future growth.
Lake Street
Ben Haynor
Strong Buy
Maintains
$4.5 → $4
2025-03-11
Reason
Lake Street
Ben Haynor
Price Target
$4.5 → $4
2025-03-11
Maintains
Strong Buy
Reason

Valuation Metrics

The current forward P/E ratio for Lifeward Ltd (LFWD.O) is -1.95, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Lifeward Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.59
Current PE
-1.95
Overvalued PE
-1.35
Undervalued PE
-5.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.55
Undervalued EV/EBITDA
-0.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.19
Current PS
0.32
Overvalued PS
8.69
Undervalued PS
-0.32

Financials

AI Analysis
Annual
Quarterly

Whales Holding LFWD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Lifeward Ltd (LFWD) stock price today?

The current price of LFWD is 6.35 USD — it has increased 4.79

What is Lifeward Ltd (LFWD)'s business?

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

What is the price predicton of LFWD Stock?

Wall Street analysts forecast LFWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFWD is4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lifeward Ltd (LFWD)'s revenue for the last quarter?

Lifeward Ltd revenue for the last quarter amounts to 6.20M USD, increased 1.09

What is Lifeward Ltd (LFWD)'s earnings per share (EPS) for the last quarter?

Lifeward Ltd. EPS for the last quarter amounts to -2.37 USD, decreased -43.97

How many employees does Lifeward Ltd (LFWD). have?

Lifeward Ltd (LFWD) has 80 emplpoyees as of March 11 2026.

What is Lifeward Ltd (LFWD) market cap?

Today LFWD has the market capitalization of 9.68M USD.